Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00338143 |
This is a Phase IIIb, open label, uncontrolled, multicenter study designed to evaluate the safety and tolerability of 12 weeks of subcutaneously administered efalizumab in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy and may also be receiving topical therapies, PUVA, or UVB phototherapy during the efalizumab treatment period.
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: efalizumab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase IIIb, Open-Label, Multicenter Study to Evaluate the Safety of 1.0 Mg/Kg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned From Systemic Therapies |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ACD2782g |
Study First Received: | June 15, 2006 |
Last Updated: | June 15, 2006 |
ClinicalTrials.gov Identifier: | NCT00338143 |
Health Authority: | United States: Food and Drug Administration |
Plaque psoriasis Antipsoriatic |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |